secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2023-10-24T23:59:59+00:00
Accession:  0001022079-23-000154
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics Q3 revenue $2.30B (-7.7% YoY); adjusted EPS $2.22; base business up 4.6%
--------------------------------------------------------------------------------

- Reported diluted EPS $1.96 (down 9.7% YoY); adjusted diluted EPS $2.22 (down 5.9% YoY).
- Base business revenue $2.27B (+4.6% YoY); COVID-19 testing revenue $26M (down 92% YoY).
- FY2023 guidance: revenue $9.19B-$9.24B, adjusted EPS $8.65-$8.75, raised low end from prior.
- Successfully negotiated all strategic health plan renewals for 2023; cites strong physician/hospital channels.
- Operating cash flow $207M in Q3 vs $502M year ago; capex $105M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/0001022079-23-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000102207923000154/dgx-20231024.htm
  HTML page:      https://secwatch.observer/filing/0001022079-23-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer